INDUCTION OF SEVERE DISEASE IN HAMSTERS BY TWO SANDFLY FEVER GROUP VIRUSES, PUNTA TORO AND GABEK FOREST (PHLEBOVIRUS, BUNYAVIRIDAE), SIMILAR TO THAT CAUSED BY RIFT VALLEY FEVER VIRUS

2003 ◽  
Vol 69 (3) ◽  
pp. 269-276 ◽  
Author(s):  
ANN F. FISHER ◽  
HILDA GUZMAN ◽  
ROBERT B. TESH ◽  
JESSICA TONRY ◽  
SHU-YUAN XIAO ◽  
...  
Keyword(s):  
Rift Valley ◽  
Rift Valley Fever ◽  
Rift Valley Fever Virus ◽  
Severe Disease ◽  
Fever Virus ◽  
Valley Fever

scholarly journals An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus

2009 ◽  
Vol 137 (9) ◽  
pp. 1309-1318 ◽  
Author(s):  
M. T. HEISE ◽  
A. WHITMORE ◽  
J. THOMPSON ◽  
M. PARSONS ◽  
A. A. GROBBELAAR ◽  
...  
Keyword(s):  
Rift Valley ◽  
Rift Valley Fever ◽  
Rift Valley Fever Virus ◽  
Fluorescent Antibody ◽  
Severe Disease ◽  
Neutralizing Antibody ◽  
Fever Virus ◽  
Antibody Responses ◽  
Valley Fever

SUMMARYRift Valley fever virus (RVFV) is a mosquito-transmitted bunyavirus (genusPhlebovirus) associated with severe disease in livestock and fatal encephalitis or haemorrhagic fever in a proportion of infected humans. Although live attenuated and inactivated vaccines have been used in livestock, and on a limited scale in humans, there is a need for improved anti-RVFV vaccines. Towards this goal, Sindbis virus replicon vectors expressing the RVFV Gn and Gc glycoproteins, as well as the non-structural nsM protein, were constructed and evaluated for their ability to induce protective immune responses against RVFV. These replicon vectors were shown to produce the RVFV glycoproteins to high levelsin vitroand to induce systemic anti-RVFV antibody responses in immunized mice, as determined by RVFV-specific ELISA, fluorescent antibody tests, and demonstration of a neutralizing antibody response. Replicon vaccination also provided 100% protection against lethal RVFV challenge by either the intraperitoneal or intranasal route. Furthermore, preliminary results indicate that the replicon vectors elicit RVFV-specific neutralizing antibody responses in vaccinated sheep. These results suggest that alphavirus-based replicon vectors can induce protective immunity against RVFV, and that this approach merits further investigation into its potential utility as a RVFV vaccine.

scholarly journals Inhibition of Rift Valley Fever Virus Replication and Perturbation of Nucleocapsid-RNA Interactions by Suramin

2014 ◽  
Vol 58 (12) ◽  
pp. 7405-7415 ◽  
Author(s):  
Mary Ellenbecker ◽  
Jean-Marc Lanchy ◽  
J. Stephen Lodmell
Keyword(s):  
Rift Valley ◽  
Rift Valley Fever ◽  
Rna Binding ◽  
Therapeutic Potential ◽  
Rift Valley Fever Virus ◽  
Severe Disease ◽  
Fever Virus ◽  
Valley Fever ◽  
Ribonucleoprotein Complexes

ABSTRACTRift Valley fever virus (RVFV) is an emerging infectious pathogen that causes severe disease in humans and livestock and has the potential for global spread. There are currently no proven safe and effective treatment options for RVFV infection. Inhibition of RNA binding to RVFV nucleocapsid protein (N) represents an attractive antiviral therapeutic strategy because several essential steps in the RVFV replication cycle involve N binding to viral RNA. In this study, we demonstrate the therapeutic potential of the drug suramin by showing that it functions well as an inhibitor of RVFV replication at multiple stages in human cell culture. Suramin has been used previously to treat trypanosomiasis in Africa. We characterize the dynamic and cooperative nature of N-RNA binding interactions and the dissociation of high-molecular-mass ribonucleoprotein complexes using suramin, which we previously identified as an N-RNA binding inhibitor in a high-throughput screen. Finally, we elucidate the molecular mechanism used by suraminin vitroto disrupt both specific and nonspecific binding events important for ribonucleoprotein formation.

scholarly journals Characterization of Two Neutralizing Antibodies against Rift Valley Fever Virus Gn Protein

Viruses ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 259
Author(s):  
Meng Hao ◽  
Guanying Zhang ◽  
Shengnan Zhang ◽  
Zhengshan Chen ◽  
Xiangyang Chi ◽  
...  
Keyword(s):  
Rift Valley ◽  
Neutralizing Antibodies ◽  
Rift Valley Fever ◽  
Rift Valley Fever Virus ◽  
Severe Disease ◽  
Fever Virus ◽  
Host Cells ◽  
Valley Fever ◽  
Endosomal Membranes ◽  
Domain Iii

The Rift Valley fever virus (RVFV) is an arthropod-borne virus that can not only cause severe disease in domestic animals but also in humans. However, the licensed vaccines or available therapeutics for humans do not exist. Here, we report two Gn-specific neutralizing antibodies (NAbs), isolated from a rhesus monkey immunized with recombinant human adenoviruses type 4 expressing Rift Valley fever virus Gn and Gc protein (rHAdV4-GnGcopt). The two NAbs were both able to protect host cells from RVFV infection. The interactions between NAbs and Gn were then characterized to demonstrate that these two NAbs might preclude RVFV glycoprotein rearrangement, hindering the exposure of fusion loops in Gc to endosomal membranes after the virus invades the host cell. The target region for the two NAbs is located in the Gn domain III, implying that Gn is a desired target for developing vaccines and neutralizing antibodies against RVFV.

Complement fixation reaction of Rift Valley fever virus

1950 ◽  
Vol 5 (5) ◽  
pp. 243-247
Author(s):  
Minoru MATSUMOTO ◽  
Saburo IWASA ◽  
Motosige ENDO
Keyword(s):  
Rift Valley ◽  
Rift Valley Fever ◽  
Complement Fixation ◽  
Rift Valley Fever Virus ◽  
Fever Virus ◽  
Valley Fever ◽  
Fixation Reaction

scholarly journals The Use of Nanotrap Particles in the Enhanced Detection of Rift Valley Fever Virus Nucleoprotein

PLoS ONE ◽  
2015 ◽  
Vol 10 (5) ◽  
pp. e0128215 ◽  
Author(s):  
Nazly Shafagati ◽  
Lindsay Lundberg ◽  
Alan Baer ◽  
Alexis Patanarut ◽  
Katherine Fite ◽  
...  
Keyword(s):  
Rift Valley ◽  
Rift Valley Fever ◽  
Rift Valley Fever Virus ◽  
Fever Virus ◽  
Valley Fever

scholarly journals Production of small ruminant morbillivirus, rift valley fever virus and lumpy skin disease virus in CelCradle™ -500A bioreactors

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Halima Rhazi ◽  
Najete Safini ◽  
Karima Mikou ◽  
Meryeme Alhyane ◽  
Khalid Omari Tadlaoui ◽  
...  
Keyword(s):  
Disease Virus ◽  
Skin Disease ◽  
Rift Valley ◽  
Rift Valley Fever ◽  
Rift Valley Fever Virus ◽  
Fever Virus ◽  
Valley Fever ◽  
Lumpy Skin Disease ◽  
Lumpy Skin Disease Virus ◽  
Cell Factories

Abstract Background Animal vaccination is an important way to stop the spread of diseases causing immense damage to livestock and economic losses and the potential transmission to humans. Therefore effective method for vaccine production using simple and inexpensive bioprocessing solutions is very essential. Conventional culture systems currently in use, tend to be uneconomic in terms of labor and time involved. Besides, they offer a limited surface area for growth of cells. In this study, the CelCradle™-500A was evaluated as an alternative to replace conventional culture systems in use such as Cell factories for the production of viral vaccines against small ruminant morbillivirus (PPR), rift valley fever virus (RVF) and lumpy skin disease virus (LSD). Results Two types of cells Vero and primary Lamb Testis cells were used to produce these viruses. The study was done in 2 phases as a) optimization of cell growth and b) virus cultivation. Vero cells could be grown to significantly higher cell densities of 3.04 × 109 using the CelCradle™-500A with a shorter doubling time as compared to 9.45 × 108 cells in Cell factories. This represents a 19 fold increase in cell numbers as compared to seeding vs only 3.7 fold in Cell factories. LT cells achieved modestly higher cell densities of 6.7 × 108 as compared to 6.3 × 108 in Cell factories. The fold change in densities for these cells was 3 fold in the CelCradle™-500A vs 2.5 fold in Cell factories. The titers in the conventional system and the bioreactor were not significantly different. However, the Cell-specific virus yield for rift valley fever virus and lumpy skin disease virus are higher (25 virions/cell for rift valley fever virus, and 21.9 virions/cell for lumpy skin disease virus versus 19.9 virions/cell for rift valley fever virus and 10 virions/cell for lumpy skin disease virus). Conclusions This work represents a novel study for primary lamb testis cell culture in CellCradle™-500A bioreactors. In addition, on account of the high cell densities obtained and the linear scalability the titers could be further optimized using other culture process such us perfusion.

Sign in / Sign up

Export Citation Format

Share Document